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Inhibition of experimental neointimal hyperplasia
by recombinant human thrombomodulin coated
ePTFE stent grafts
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Michael J. Rohrer, MD,a and Bruce S. Cutler, MD,a Worcester, Mass
Objectives: The goal of this study was to evaluate the ability of recombinant human thrombomodulin (rTM) to inhibit
neointimal hyperplasia when bound to expanded polytetrafluoroethylene (ePTFE) stent grafts placed in a porcine balloon
injured carotid artery model.
Methods: The left carotid artery of male pigs, weighing 25 to 30 Kg, was injured with an angioplasty balloon. Two weeks
later either a non-coated standard ePTFE stent graft (Viabahn, 6  25 mm, W. L. Gore & Associates) or a rTM coated
stent graft was implanted into the balloon-injured segment using an endovascular technique. Carotid angiography was
performed at the time of the balloon injury, two weeks later and then at 4 weeks to assess the degree of luminal stenosis.
One month after stent graft deployment, the grafts were explanted following in situ perfusion fixation for histological
analysis. The specimens were then cross-sectioned into proximal, middle and distal segments, and the residual arterial
lumen and intimal to media (I/M) ratios were calculated with computerized planimetry.
Results: rTM binding onto ePTFE-grafts was confirmed by functional activation of protein C and histopathology
with immuno-scanning electron microscopy, backscatter electron emission imaging and x-ray microanalysis. All
seven of the rTM coated stent grafts and six of the seven uncoated stent grafts were patent at the time of explantation.
The mean luminal diameter of the rTM coated stents was 93%  2.0% of the original diameter, compared with 67%  23%
(P .006) in the control group. Histological analysis demonstrated that the area obliterated by intimal hyperplasia at the
proximal portion of the rTM stent was27% compared with the control group: (2.73 0.69 mm2, vs 3.47 0.67 mm2,
P <.05).
Conclusions: Neointimal hyperplasia is significantly inhibited in ePTFE stent grafts coated with rTM compared with
uncoated grafts, as documented by improved luminal diameter by angiography and by computerized planimetry
measurements of residual lumen area. These findings suggest that binding of recombinant human thrombomodulin onto
ePTFE grafts may improve the long-term patency of covered stents grafts. ( J Vasc Surg 2008;47:608-15.)
Clinical Relevance: Decrease of neointimal hyperplasia of the magnitude observed in this study could significantly
improve blood flow and patency of small caliber prosthetic grafts. If the durability of these results can be confirmed by
long-term studies, this technique may prove useful in preventing graft stenosis and arterial thrombosis following
angioplasty or vascular bypass procedures.Since its clinical introduction in 1976, expanded poly-
tetrafluoroethylene (ePTFE) has been widely used as a
substitute for autogenous saphenous vein bypass grafts.1
However, its usefulness in small vessel and distal revascu-
larization continues to be hindered by luminal stenosis due
to neointimal hyperplasia.2
Neointimal hyperplasia (NH) is the predominant
pathological process leading to graft failure, mediated by
smooth muscle cell (SMC) migration and proliferation
leading to matrix deposition in response to arterial manip-
ulation and intimal trauma. Polymers3,4 and biosynthetic
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608grafts5-12 have been used in an attempt to inhibit the
progression of neointimal hyperplasia with limited success.
Anticoagulants such as heparin 5,7,8,10,11 prostaglandins6
and thrombolytic derivatives9,12 have no significant effect
on the development of neointimal hyperplasia.7
Thrombomodulin (TM) is an endothelial cell surface
glycoprotein,13 whose anticoagulant properties arise from
binding thrombin. The thrombomodulin-thrombin com-
plex inhibits the procoagulant properties of thrombin,
which in turn activates the anticoagulant zymogen pro-
tein C, which potently inhibits thrombus formation. The
anticoagulant properties of thrombomodulin13-17 and
molecular structure15-17 have been studied extensively.
Our laboratory demonstrated that recombinant human
thrombomodulin (rTM) was also a potent antimitogenic
molecule. It inhibits smooth muscle cell proliferation in
vitro,18 and decreases neointimal hyperplasia in a rabbit
femoral artery balloon-injury model.19 We also reported
that rTM can be bonded to ePTFEmaterial in vitro and still
function to activate protein C after a period of continuous
flow simulation.20 A preliminary study of rTM bound to
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timal formation in a porcine carotid artery bypass model
(data not shown). The purpose of this study was to evaluate
the feasibility of binding rTM to ePTFE stent grafts and to
study its ability to inhibit neointimal hyperplasia in a por-
cine balloon injured carotid artery model.
METHODS
Stent graft preparation and evaluation
Binding of rTM to ePTFE stent grafts. Viabahn
ePTFE stents (6 25mm, internodal distance 25microns,
stent bound to the outside of the ePTFE graft, W. L. Gore
& Associates, Inc, Flagstaff, Ariz),were coated with recom-
binant human-soluble thrombomodulin TMD1 (CS)
(rTM, donated by Eli Lilly and Co, Indianapolis, Ind)
using a two step binding technique.18 The stent grafts were
initially treated with a carbodiimide cross-reacting agent
(EDAC, 1-ethyl-3-(3-diamethylaminoprophyl) carbodiim-
ide, Sigma, St. Louis, MO) at a concentration of 10 mg/ml
in water (Milli-Q water, Millipore Corp., Billerica, Mass)
for 60 minutes at 4°C. After washing the stents twice with
water, they were then incubated with rTM 15 g/cm2 in
Tris-HCL buffer (pH 7.4, Sigma) for 48 hours at 4°C.
Evaluation of rTM Bound ePTFE stents. The pres-
ence of functional rTM on the ePTFE stent grafts was
evaluated with an activated protein C (APC) assay.18 One
rTM coated ePTFE stent graft was cross-sectioned into
three segments for analysis. Two segments were assessed
for APC activity, and the other was subjected to immuno-
SEM evaluation. Of the two stent segments for APC activ-
ity study, the first was evaluated for binding of rTM to the
luminal surface and the second for whole stent segment
rTM binding. The first segment was opened longitudinally
and the inner surface exposed to evaluate the luminal
surface. It was then fixed to the base of a 24-well plate
(Corning Inc., Corning, NY). For whole stent evaluation,
the entire section of the stent was placed into the 24-well
plate with both the luminal and stent strut surfaces
exposed.
Both rTM coated stent graft segments were then
incubated with 1 unit/ml of human plasma thrombin
(Sigma) at 37°C for 60 minutes followed by incubation
with 5 g/ml of human protein C (Enzyme Research
Laboratories, South Bend, Ind) at 37°C for 60 minutes.
Then, 150 l of each sample solution was transferred to
a 96-well plate in triplicate. An aliquot of hirudin was
added to each well (final concentration 30 nM) for 4
minutes to stop thrombin function. Chromogenic sub-
strate S2366 (Chromogenix, DiaPharma Group Inc.,
West Chester, Ohio) was then added to each well (final
concentration 0.4 mM). The reaction was stopped using
30 l of 20% acetic acid in each well after 30 minutes,
and the samples were immediately analyzed for optical
density at 405 nm with a spectrophotometer (SLT Spec-
tra, TECAN US, Inc., Durham, NC).Immunoscanning electron microscopy
The rTM coated ePTFE stent segments were incubated
with monoclonal mouse antihuman endothelium throm-
bomodulin antibody QBEND/40 (Harlan Sera-Lab Lim-
ited, San Francisco, Calif) at a 1:10 dilution in incubation
buffer (PBS plus 0.1% bovine serum albumin) at 4°C
overnight, followed by incubation with a second antibody,
AURION immunogold goat anti-mouse IgG (Electron
Microscopy Sciences [EMS], Hatfield, Pa) at 22°C for 2
hours. After washing with incubation buffer and water, the
samples were subjected to R-GENT developer and silver
enhancer (EMS) for 20 minutes followed by water wash
and then kept in water for scanning electron microscopy
(SEM) evaluation.
Scanning electron microscopy and x-ray microanalysis
with energy dispersive spectroscopy
Immunogold stained and silver impregnated enhanced
stent graft samples with and without rTM coating were
dehydrated with ethanol and critical-point-dried with CO2.
The samples were thenmounted onto aluminum stubs with
silver conductive paste and sputtered-coated with gold/
palladium. The inner surface of the samples was examined
using an ETEC autoscan scanning electron microscope
(ETEC Corporation Inc., Hayward, Calif) at 20 kV accel-
erating voltage.
The immunogold stained and silver enhanced rTM
coated stent graft samples were also secured to SEM stubs
with pure carbon tape and conductive colloidal graphite.
Approximately 10 nm of carbon was evaporated onto the
surface to stabilize the material in the electron probe. The
ePTFE stent samples were then examined using back scat-
ter electron emission imaging (BSI) at X1000. Atomic
contrast images were recorded using a Cameca SX50 elec-
tron microprobe equipped with a Robinson fast scan BSI
detector (Cameca Inc., Courbevoie, France). Metal parti-
cles identified in BSI were analyzed using a PGT PRISM
digital energy dispersive detector (Princeton-Gamma-Tech
Inc., Princeton, NJ) and their x-ray spectrums were re-
corded.Microanalyses were counted for 30 seconds over an
energy range of 0 to 10 keV. The detector resolution was
approximately 150 eV.
Surgical procedures
Male Yorkshire pigs weighing 25 to 30 Kg were anes-
thetized with Telazol 5 mg/Kg, ketamine 2.5 mg/Kg, and
xylazine 2.5 mg/Kg intramuscularly, and general anesthe-
sia maintained with isoflurane 1% to 3%. The left common
femoral artery was cannulated with an 8F introducer. A bolus
of heparin 5000 IU was administered intra-arterially after
sheath insertion and an additional 2500 IU was given just
prior to stent graft deployment. A 5F pigtail catheter was
directed over a guidewire, under fluoroscopic guidance,
into the aortic arch where a flush aortic arch angiogram was
obtained. Next, a selective arteriogram of the left common
carotid artery was obtained using a 5F Berstein catheter and
marker wire. Arterial dimensions were obtained with a
arter
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tronic calipers, prior to arterial injury. A 6.0  20 mm
ultra-soft angioplasty balloon (Boston Scientific Corp.,
Natick, Mass) was then positioned in the left common
carotid artery between the second and third cervical verte-
brae. The balloon was expanded to 6.4 mm at 10 atmo-
spheres, rotated 360 degrees, moved up and down 0.5 cm,
and deflated and re-inflated twice to stimulate neointimal
hyperplasia. Completion angiograms were obtained in the
anterior-posterior (AP) and lateral anterior oblique (LAO)
projections.
The ePTFE stent grafts were deployed 4 weeks after
balloon injury through a surgical incision to expose the left
common femoral artery. The pigs were randomly assigned
to receive either a rTM coated or non-coated 6  25 mm
ePTFE stent graft delivered over a 0.035 inch Amplatz
guidewire, and deployed in the left common carotid artery
between the second and third cervical vertebrae. Comple-
tion arteriograms were obtained in AP and LAO projec-
tions for comparative analysis (Fig 1, A, B, and C). All pigs
received acetylsalicylic acid 325 mg daily until termination.
Specimen collection
The animals were sacrificed 4 weeks after stent graft
placement. After inducing general anesthesia, selective left
common carotid arteriograms were obtained through sur-
gical exposure of the artery. An 8F infusion catheter was
inserted into the proximal left common carotid artery and,
using inflow occlusion, an arteriogram was obtained in two
views. The animals were then exsanguinated, followed by
fixation of the common carotid artery by antegrade perfu-
sion with 4% paraformaldehyde at 120 to 140 mm Hg
pressure for 30 minutes. The entire left common carotid
artery including the stent graft was resected en bloc and
stored in 4% paraformaldehyde for histopathological eval-
uation. Arteriographic data were recorded for comparison
with preoperative measurements to assess the development
of neointimal hyperplasia.
After 24 hours of fixation, the specimens were dehy-
drated and embedded in araldite in a cylindrical mold with
the long axis perpendicular to the cutting plane. Transverse
sections 100 m were cut with a diamond wafering blade
Fig 1. Angiographic digital images of the left carotid ar
weeks after angioplasty, prior to stent graft deploymen
covered stent graft deployed in the left common carotidfrom the proximal, middle and distal segments of each stentgraft. The ePTFE and the stent wires were left in place to
avoid potential artifact or damage to the stent graft. The cut
sections were then polished to approximately 30 m and
mounted on glass slides.
Histopathological analysis
One of the rTM-coated and one of the uncoated stent
grafts were sectioned longitudinally for gross inspection.
Cross-sectional images were obtained using a LeicaMZ 7.5
dissecting stereomicroscope (Leica Microsystems, Ban-
nockburn, Ill) at X2.5 magnification. The imaging system
was calibrated with a stage micrometer. The cross-sectional
areas of the vessel lumen, stent lumen, intima, media, and
whole artery were measured using Image J software Na-
tional Center for Biotechnology Information (NCBI, Be-
thesda, Md). The ratios of intima to media (I/M) were
calculated.
Statistical analysis
The data were analyzed using variance for mixed mod-
els by restricted maximum likelihood estimation (REML)
using the SAS procmixed procedure.21,22 Compliance with
the assumption of normality for the distribution of residuals
was evaluated graphically using frequency histograms
as well as by the Kolmogorov-Smirnov goodness of fit
test.23,24 Differences were considered significant at the 95%
confidence level (P  .05).
The results of luminal area, neointimal area, media area,
whole artery area, and I/M ratio and lumen to whole artery
(L/A) ratio are expressed as the mean  SD of proximal,
middle, and distal segments, n  5. The effect of ratios vs
left carotid artery segment (proximal 1/3, middle 1/3,
distal 1/3), and treatment (rTM-coated and uncoated
stent graft) were evaluated using analysis of variance for
mixed models. The effect of luminal diameter of angio-
grams vs segment (proximal 1/3, middle 1/3, distal 1/3),
and treatment (rTM-coated and uncoated stent graft) were
evaluated using analysis of univariate analysis of variance for
mixed models two-pair t test, n  7. Results are reported
after applying a Bonferroni adjustment to compensate for
chance false discoveries presuming 100 multiple compari-
A, Digital subtraction image of the balloon injury site 2
nd C, Unsubstracted images of a 6  25 mm ePTFE
y at the balloon-injured site.tery.
t. B asons.
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A total of 14 stent grafts were deployed in the left
common carotid artery of 14 pigs; seven rTM coated and
seven uncoated. There were no periprocedural complica-
tions or deaths. At the time the grafts were harvested, all of
the rTM coated stents were patent, while one of the seven
uncoated stents had thrombosed.
Bonding of rTM to stent grafts
Scanning electron microscopy, both secondary imaging
and backscatter (ie, atomic contrast) imaging, was performed
on the immuno-stained and silver enhanced luminal surfaces
of the ePTEF stent graft (Fig 2,A, B, C, andD). The presence
of silver enhanced-immuno labeled rTMmolecules bound to
the nodal and internodal strands of the ePTFE are easily seen
in the backscatter image (Fig 2,C) as bright spots throughout
the image. The stent graft that we used in this study was a
Nitinol stent (Boston Scientific Corp., Natick, Mass). The
titanium and nickel are components of Nitinol. X-ray micro-
analysis of the bright objects (Fig 2, D) and the elemental
spectrum for silver (Ag) confirms the presence of silver en-
hanced, immuno-labeled rTM on the luminal surface of the
stent graft.
The presence of activated protein C was used to
confirm the bonding of functional rTM to the stent
grafts (Fig 3). No protein C activity could be demon-
Fig 2. SEM and back scatter electron emission image (
bound to ePTFE.C, BSI demonstrates silver tagged rTM
presence of Ag bonded rTM molecules.strated for control ePTFE grafts placed in buffered sa-line, whereas the rTM coated stent grafts showed 77.5%
increase in APC activity on the luminal surface, and
86.8% on whole stent graft, indicating that both surfaces
of the stent graft were coated with functional rTM. Thus,
the combination of electron microscopy and activated
protein C analysis demonstrated the presence of active
molecules of rTM on all surfaces of the coated stent
A, SEM of normal ePTFE. B, SEM of rTM molecules
ecules (white particles);D, X-ray microanalysis shows the
Fig 3. Optical density of activated protein C. The functional
presence of rTM on the luminal surface of the rTM coated stent
graft and the whole rTM coated stent graft was evaluated with
activated protein C. The whole structure of rTM-coated stent graft
expressed significantly more activated protein C than the luminal
surface alone.BSI).
molgrafts.
regul
imal.
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The residual luminal diameter wasmeasured by angiog-
raphy. For the rTM coated stent graft group the residual
diameter was 93%  2.0% of the pre-stent value. The
luminal diameter of the uncoated group was reduced to
67.2%  22.7% (P  .006).
On gross inspection of the harvested grafts 4 weeks
after deployment, the rTM coated stents were covered with
a thin, glistening white layer (Fig 4,A and B). There was no
mural thrombus or fibrin present. The proximal and distal
Fig 4. Gross photographs of the luminal surface of
rTM-coated ePTFE stent graft is covered with a smooth
B, The uncoated ePTFE stent graft is covered with an ir
Fig 5. Light microscopic images of a representative tran
4 weeks after deployment in the left carotid artery. Unco
Distal. rTM-coated ePTFE covered stent graft. D, Proxmargins of the stent graft had a smooth tapering layer ontothe native vessel (Fig 4, A). By contrast, an irregularly
thickened yellowish intraluminal layer covered the un-
coated stent grafts. There were focal areas of red blood clot
and fibrin deposition. The inner surface of the stent grafts
was irregular at both the proximal and distal ends (Fig 4, B).
As noted above, one of the uncoated stent grafts had
thrombosed prior to harvest.
Light microscopy combined with computerized
planimetry was used to measure cross-sectional areas and to
calculate I/M ratios for rTM treated and control speci-
E covered stent grafts explanted at 4 weeks. A, The
ening white thin layer with minimal surface deposition.
ar thick yellow-brown layer with scattered blood clots.
section of uncoated and rTM-coated ePTFE stent graft
ePTFE covered stent graft. A, Proximal. B, Middle. C,
E, Middle. F, Distal.ePTF
, glistsverse
atedmens. The rTM coated stent graft had a larger lumen area
lumen
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 3 Wong et al 613and less neointimal thickening than the control stent graft.
(Fig 5, A, B, C, D, and F) The data for lumen, neointima,
media and whole artery areas, and I/M ratio and L/A ratio
are listed in the Table. The cross-sectional areas of neoin-
timal thickening observed for the proximal, middle, and
distal segments of the rTM stent grafts and the control
groups are shown in Fig 6,A. There was a27% (P .05)
reduction in neointimal thickening of the proximal seg-
ment, 15.8% (NS) for the middle, and 12.9% not
significant (NS) for the distal segment. The results for
the I/M ratios were similar (Fig 6, B). There was 39%
(P  .05) reduction for the proximal, 7.95% (NS) for
the middle, and 18.7% (NS) for the distal segments.
Consequently, histological analysis showed that rTM
effectively reduced neointimal hyperplasia and that the
effect was most pronounced in the proximal segment of
Table. Histomorphometric measurement: Areas of lumen
(Stent graft) Location Lumen (mm2) Neointima (mm2)
Uncoated Proximal 7.34  0.99 3.74  0.67
Middle 9.94  0.67 3.79  1.61
Distal 8.96  0.56 2.93  0.70
rTM bound Proximal 9.02  0.39 2.73  0.69
Middle 11.31  0.47 3.19  0.80
Distal 10.14  0.66 2.56  1.40
rTM, Recombinant human thrombomodulin; I/M, intimal to media; L/A,
Fig 6. Neointima area (A) and intima tomedia (I/M) ratio (B) of
rTM coated and uncoated stent grafts.the coated stent graft.The luminal area of the proximal, middle, and distal
stent graft cross sectional segments is shown in Fig 7.
The luminal areas of the rTM coated stents were 9.02 
0.39 mm2, 11.31  0.47 mm2, and 10.14  0.66 mm2,
respectively. In the corresponding segments of the un-
coated stent graft group, the values were 7.34  0.99
mm2, 9.94  0.67 mm2, and 8.96  0.56 mm2, respec-
tively. The overall difference between the luminal areas
of the two groups was 1.176 mm2 (P  .05). Angiographi-
cally, the luminal diameter was 4.81  0.05 mm prior to
balloon injury, and 4.29  0.15 mm 2 weeks after balloon
injury, P  .001. Four weeks after stent graft placement, the
diameter of the control stent graft group was 3.16  0.22
mm, and the rTM coated stent graft group was 4.48  0.03
mm, P .02.
DISCUSSION
Re-stenosis produced by neointimal hyperplasia limits the
success of angioplasty and stenting of small caliber peripheral
arteries. Patency rates as low as 38% and 8% for 1 and 3 years,
respectively, have been reported for angioplasty and stenting
of the femoropopliteal segment.25There have beenno reports
of successful stent grafting for femoropopliteal occlusive dis-
ease.26 Previous studies have shown that rTM is a potent
inhibitor of neointimal hyperplasia, because of its antithrom-
botic and antimitogenic properties.20 To take advantage of
the favorable characteristics of rTM requires a delivery system
that can place a high concentration of rTM at the site of
intima, media, and whole artery (mean  SD)
ia (mm2) Whole artery (mm2) I/M ratio L/A ratio
5  1.15 19.65  2.66 0.77  0.05 0.37  0.08
8  1.29 22.96  2.03 0.63  0.21 0.37  0.08
5  1.48 21.95  2.83 0.52  0.12 0.43  0.04
1  1.40 20.07  2.63 0.47  0.15 0.36  0.07
7  2.53 24.03  3.15 0.58  0.17 0.41  0.08
2  2.21 21.80  2.41 0.42  0.18 0.41  0.11
to whole artery.
Fig 7. Luminal area of the rTM-coated and uncoated ePTFE
stent grafts. The mean luminal area of each segment of the rTM-
coated stent graft was larger in each segment compared with
uncoated stent graft with an overall luminal area difference of
1.176 mm2 (P  .05)., neo
Med
5.0
5.9
5.8
6.0
6.1
6.0arterial injury. Systemic therapy is not practical because rTM is
JOURNAL OF VASCULAR SURGERY
March 2008614 Wong et alrapidly diluted by the circulating blood volume, metabolized
by the liver, and excreted by the kidney. The present study
evaluated covalent bonding rTM to endovascular ePTFE
stent grafts, so as to deliver a high concentration of rTM
directly to the site of arterial injury.
In order to control neointimal hyperplasia, it is important
to prevent arterial spasm and remodeling after injury, aswell as
the inflammatory reaction and proliferative effects of smooth
muscle cells. The rTM coated ePTFE stent graft circumvents
the problems associated with systemic therapy as well as the
uncontrolled leaching of the drug from the surface of a poly-
mer based delivery device. By coating all surfaces of ePTFE
stent grafts with rTM, the anticoagulant, antimitogenic, and
anti-inflammatory properties of rTM are concentrated at the
site of tissue injury, thereby maximizing the local suppressant
effect on the smooth muscle cells and inflammatory reaction
that initiate the hyperplastic process.
This study demonstrated the feasibility of bonding rTM
to 6 mm ePTFE covered stent grafts as confirmed by im-
muno-scanning electron microscopy, back scatter imaging,
and x-ray microanalysis. The presence of functional rTM
bound to ePTFE grafts was verified by demonstrating the
presence of activated protein C. The rTM coated stent grafts
reduced neointimal hyperplasia, compared with non-coated
stents in a porcine balloon injurymodel, as judgedby the gross
appearance, angiographically maintained luminal diameter,
histological analysis of residual luminal, and improved I/M
ratios.
Following implantation of a stent graft, flow turbulence
occurs preferentially in the proximal segment. The resultant
change in hemodynamicsmay explain the observed increase in
neointimal formation in this segment shown in Fig 6 of the
control group. Compared with the control group, the neoin-
tima and I/M ratio in the proximal segment of the rTM
coated stent group was significantly less. The primary limita-
tions of this study are the relatively small number of experi-
mental animals and the short duration of follow-up. It is
possible that a larger study might have shown significant
inhibition of hyperplasia in the middle and distal segments as
well as the proximal segments of the rTM coated stent grafts.
On the other hand, amore extensive study could confirm that
the primary inhibitory effect of neointimal hyperplasia indeed
is in the proximal segment where the most active hyperplasia
appears to occur. The encouraging results noted here, have
prompted us to undertake a larger study with longer fol-
low-up to answer this question and to evaluate the duration of
the antihyperplastic effects of rTM.
CONCLUSION
Thrombomodulin, by virtue of its anticoagulant, antimi-
togenic, and anti-inflammatory properties, appears to be an
attractive choice as a surface-binding agent. The preliminary
findings of this study suggest that coating a 6 mm diameter
ePTFE stent graft with recombinant human thrombomodu-
lin will inhibit neointimal hyperplasia and preserve luminal
patency as confirmedby angiography and cross-sectionalmor-
phometric evaluation. This technique may prove to be a
practical means to prevent restenosis and early proceduralfailure following angioplasty or open vascular bypass opera-
tions.
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